Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Yakugaku Zasshi ; 142(6): 589-591, 2022.
Article in Japanese | MEDLINE | ID: mdl-35650077

ABSTRACT

The current adolescent and young adult (AYA) generation represents a unique age group, among whom life changes dramatically due to living environments including school, seeking employment, marriage, and pregnancy, and due to lack of a social support system for cancer during the AYA years. The 3rd term of the Basic Plan for Cancer Control Promotion has stimulated increased momentum toward medical community involvement with AYA generation cancer patients, leading to the establishment of a Department of Cancer in the AYA Generation at our hospital. While promoting provision of highest quality team-based medical care, we have also been working to provide the best daily life/social life support, using our abundance of treatment experience, and taking into consideration various problems peculiar to AYA individuals, including anxiety about the future, a desire to preserve fertility, and a need for reproductive support. Pharmacists are involved in pharmacotherapy as part of medical treatments for AYA patients, aiming to provide optimal pharmacotherapy based on the practice of accurate pharmaceutical management. We foster collaborations between various clinical departments to tackle AYA-specific issues including preservation of fertility. Future challenges to address include long-term follow-up on such issues as late-stage disorders and endocrine disorders after AYA patient cancer treatment. Under current circumstances, our time for face-to-face interaction with patients as members of the hospital's medical staff is limited. Currently, we are involved in the operation of a breast cancer salon that aims to improve breast cancer patients' quality of life by supporting these patients during diagnosis and treatment.


Subject(s)
Breast Neoplasms , Quality of Life , Adolescent , Delivery of Health Care , Female , Humans , Pregnancy , Young Adult
2.
Ann Pharmacother ; 55(10): 1195-1202, 2021 10.
Article in English | MEDLINE | ID: mdl-33543634

ABSTRACT

BACKGROUND: In high-dose methotrexate (HD-MTX) therapy, delayed elimination of MTX from plasma leads to severe adverse effects. However, the risk factors for the delayed elimination of plasma MTX are still unclear. OBJECTIVE: The purpose of this study was to investigate the factors related to the delayed MTX elimination in HD-MTX monotherapy. METHODS: This retrospective study was performed on patients who received HD-MTX monotherapy between April 2009 and March 2019 at the Hiroshima University Hospital. Patients were divided into a "Normal" and a "Delayed" group according to their MTX plasma concentration at 48 or 72 hours after administration. Patient characteristics, dose of HD-MTX, MTX plasma concentration, and adverse effects were analyzed and compared between the 2 groups. RESULTS: A total of 74 patients were included in this study. Logistic analysis of patient baseline characteristics was performed to identify risk factors for delayed MTX elimination. Serum albumin (ALB) was detected as a risk factor. Univariate and multivariate analysis revealed that low ALB level (<3.7 g/dL) and type of cancer were associated with delayed MTX elimination (univariate analysis: odds ratio [OR] = 6.00, P = 0.004, and OR = 4.33, P = 0.039, respectively; multivariate analysis: adjusted OR [AOR] = 6.45, P = 0.006, and AOR = 8.11, P = 0.018, respectively). Adverse effects were not significantly different between the 2 groups, excluding renal impairment. CONCLUSIONS AND RELEVANCE: Our study showed that low ALB is a risk factor for delayed MTX elimination in HD-MTX monotherapy. Pharmacokinetic analysis is needed to establish the dose of HD-MTX in patients with a low ALB level.


Subject(s)
Methotrexate , Neoplasms , Humans , Methotrexate/adverse effects , Retrospective Studies , Risk Factors , Serum Albumin
3.
Article in English | MEDLINE | ID: mdl-32637145

ABSTRACT

BACKGROUND: Instillation of sterile graded talc in the pleural space is performed to prevent reaccumulation of malignant pleural effusion after drainage. Talc is thought to encourage pleural adhesions as part of the repair process by provoking inflammation, suggesting that adhesions are less likely to form in patients taking corticosteroids or other drugs with anti-inflammatory effects. However, the relationship between steroid therapy and pleurodesis efficacy remains unclear. CASE PRESENTATION: We report the outcomes of six patients who underwent pleurodesis at Hiroshima University Hospital while being treated with systemic steroid therapy for non-cancer-related illnesses. Talc pleurodesis was successful at the first attempt in five of the six patients. The five successful cases were receiving low-dose oral prednisolone or methyl prednisolone (range, 1-20 mg/day) at the time of pleurodesis and had serum albumin levels ranging from 2.2 to 3.0 g/dL. In contrast, the patient in whom pleurodesis was unsuccessful was receiving a higher dose of prednisolone (40 mg/day) intravenously and had a relatively low serum album level (1.7 g/dL). CONCLUSIONS: The outcome of pleurodesis may be affected by the dose and/or route of systemic steroid therapy. Further analysis with more patients will be necessary to clarify the relationship between steroid dosage and talc pleurodesis success rate.

4.
Yakugaku Zasshi ; 139(4): 629-633, 2019.
Article in Japanese | MEDLINE | ID: mdl-30930398

ABSTRACT

The combination of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin with rituximab (DA-EPOCH-R) is used for non-Hodgkin lymphoma patients. Febrile neutropenia (FN) is a common complication of treatment with myelo-suppressive chemotherapy, so preventing FN is important for maintaining chemotherapy dosage. Recently, pegfilgrastim has been used as the primary prophylaxis of FN in Japan, but there have been few cases reported using pegfilgrastim for the primary prophylaxis in DA-EPOCH-R. In this study, we retrospectively compared the efficacy of pegfilgrastim with that of filgrastim in patients receiving DA-EPOCH-R in Hiroshima University Hospital. Efficacy assessment was based on incidence of FN and serious neutropenia (neutrophil count <500/µL), hospitalization days and chemotherapy dosage level. Ten patients met the inclusion criteria: pegfilgrastim (n=5, 30 cycles) or filgrastim (n=5, 16 cycles). No difference in efficacy existed between pegfilgrastim and filgrastim in the first cycle; however, 2 of 5 patients in filgrastim group reduced dose level in the total cycles of chemotherapy, no patients in pegfilgrastim group reduced. In conclusion, pegfilgrastim seemed better than filgrastim for the primary prophylaxis in DA-EPOCH-R.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Febrile Neutropenia/chemically induced , Febrile Neutropenia/prevention & control , Filgrastim/administration & dosage , Polyethylene Glycols/administration & dosage , Rituximab/administration & dosage , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Etoposide/administration & dosage , Female , Humans , Lymphoma, Non-Hodgkin/drug therapy , Male , Middle Aged , Prednisone/administration & dosage , Retrospective Studies , Treatment Outcome , Vincristine/administration & dosage
5.
Yakugaku Zasshi ; 139(1): 131-134, 2019.
Article in English | MEDLINE | ID: mdl-30606920

ABSTRACT

When undergoing 90Y-ibritumomab tiuxetan (90Y-IT) treatment, patients are discharged from hospital soon after initiation of treatment and followed up as outpatients. Thus it is important to apprise patients of the safety information regarding 90Y-IT treatment. However, studies investigating the safety of 90Y-IT in real-world clinical practice are lacking. We sought to investigate the adverse events arising from 90Y-IT administration to patients in our hospital. Patients who received 90Y-IT treatment at Hiroshima University Hospital from April 2010 to December 2014 were eligible for this study. The medical records of the patients were reviewed retrospectively. Eleven patients (median age, 65 years) were enrolled. Patients were classified into 3 groups according to the number of prior regimens: 1, 2-3, or >3, consisting of 5, 4, and 2 patients, respectively. The number of patients with induced grade 3 and 4 hematotoxicity, respectively, was 5 and 0 for leukocytopenia, 3 and 2 for neutropenia, and 3 and 2 for thrombocytopenia. The median nadir time was 37 d for leukocytopenia, 37 d for neutropenia, 36 d for thrombocytopenia, and 43 d for anemia. Patients with 2 or more prior regimens tended to experience grade 3 or 4 hematotoxicity more frequently than those with 1 prior regimen. In conclusion, we showed that hematotoxicity is a major adverse event of 90Y-IT treatment and that the nadir time is later than that with conventional anticancer agents. Medical staff, including pharmacists, should direct attention to the initial symptoms of hematotoxicity, especially in those patients who have received several prior regimens.


Subject(s)
Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/therapeutic use , Lymphoma/drug therapy , Radiopharmaceuticals/adverse effects , Radiopharmaceuticals/therapeutic use , Yttrium Radioisotopes/adverse effects , Yttrium Radioisotopes/therapeutic use , Aged , Aged, 80 and over , Anemia/chemically induced , Antibodies, Monoclonal/administration & dosage , Asian People , Female , Humans , Japan , Leukopenia/chemically induced , Male , Middle Aged , Neutropenia/chemically induced , Retrospective Studies , Safety , Thrombocytopenia/chemically induced , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...